Peer-Reviewed Publication Demonstrates Localised Distribution of OncoSil™ Microparticles in Pancreatic Cancer Tissue

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

“This publication provides important histopathological evidence that implanted Phosphorus-32 microparticles remain confined within tumour tissue, supporting the highly localised mechanism of action of the OncoSil™ device. The findings provide further scientific validation of the technology and add to the growing body of evidence supporting its use in pancreatic cancer treatment.

We congratulate Dr Amanda Lim and her co-investigators at the Royal Adelaide Hospital and the University of Adelaide on this important contribution to the pancreatic cancer literature and thank them for their continued commitment to advancing the understanding of OncoSil™ therapy.”